MetaCap

Envoy Medical Inc. Class A (COCH)

NASDAQ: COCHHealth CareIndustrial SpecialtiesUSD

6.700.00 (0.00%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

COCH stock chart

Technical analysis

Key statistics

All statistics
Market cap
$51.89M
EPS (TTM)
-$4.57
52-week range
3.63 – 9.54
Day range
6.52 – 6.85
Volume / Avg
25.31K / 16.73K
Beta
—

52-week range

$3.63$9.54

COCH stock today

Envoy Medical (COCH) closed at $6.70 on Nov 20, essentially unchanged from the prior close, versus the S&P 500's 3.70% decline. Shares are 29.8% below their 52-week high of $9.54 and 84.6% above the 52-week low of $3.63, in the middle of the past year's range. COCH is up 913.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 829.3%.

Envoy Medical has posted a net loss over the last twelve months (EPS of -$4.57), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Envoy Medical

Company profile

Envoy Medical, Inc., a hearing health company, provides medical technologies across the hearing loss spectrum. The company's medical technologies are designed to shift the paradigm within the hearing industry and bring providers and patients the hearing devices desire. It offers personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants.

Industry
Industrial Specialties
CEO
Mr. Brent T. Lucas Esq.
Headquarters
White Bear Lake, MN
Employees
43
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, Envoy Medical generated $241,000 in revenue, up 7.1% from fiscal 2024. Envoy Medical reported a net loss of $23.8 million, compared with a loss of $20.8 million a year earlier. Gross margin was -262.7% (down from -229.8%) and operating margin -9240.7%.

Envoy Medical annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$241.00K$225.00K$316.00K$237.00K—
Growth+7.11%-28.80%+33.33%——
Net income$-23.76M$-20.80M$-29.92M$-15.92M$-251.63K
EPS (diluted)$-1.23$-1.49$-2.54$-1.57—

Analyst forecast

Forecast

Consensus (3 analysts)

strong_buy

Avg. price target

$2.17-67.61%

  • Strong buy 0
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $2.00High $2.50

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.50 vs $-0.70
Surprise
+28.57%

COCH news

All COCH news

Envoy Medical peers

Health Care sector
COCH peer companies
CompanyPrice% ChgMarket capCompare
YDDLOne and One Green Technologies. Inc Class A0.910.00%$50.99Mvs COCH
CNXUConexeu Sciences Inc.1.55-25.48%$47.79Mvs COCH
NTRBNutriband Inc.4.92-1.60%$59.81Mvs COCH
APTAlpha Pro Tech Ltd.5.96-4.49%$61.17Mvs COCH
WBXWallbox N.V. Class A1.49-13.87%$36.14Mvs COCH
MAMOMassimo Group0.8405+3.40%$35.00Mvs COCH
NTICNorthern Technologies International Corporation7.38-1.99%$71.09Mvs COCH
MYOMyomo Inc.0.811-3.45%$32.52Mvs COCH

Indexes, lists and sector

Envoy Medical stock FAQ

What is Envoy Medical's stock price today?

COCH last traded at $6.70 as of Nov 20, 4:00 PM EST, up 0.00% on the day. Prices are delayed at least 15 minutes.

Does Envoy Medical pay a dividend?

No. Envoy Medical does not currently pay a regular cash dividend.

Who is Envoy Medical's CEO?

Mr. Brent T. Lucas Esq. is the chief executive officer of Envoy Medical Inc. Class A, which has about 43 employees.

Has COCH ever split its stock?

Yes. The most recent COCH stock split was a 1-for-10 split on Oct 26, 2026.

What is the COCH 52-week high?

The 52-week high for COCH is $9.54 and the 52-week low is $3.63. The stock is currently 29.8% below its high.

Compare COCH